Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nephritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Nephritis. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2017-000992-10 Sponsor Protocol Number: FHM-1-2017 Start Date*: 2017-06-28
    Sponsor Name:Universitets klinik for nyresygdomme og Hypertension
    Full Title: Prednisolone treatment in acute interstitial nephritis
    Medical condition: Acute interstitial nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10048302 Tubulointerstitial nephritis PT
    21.1 10038359 - Renal and urinary disorders 10000819 Acute interstitial nephritis LLT
    21.1 10038359 - Renal and urinary disorders 10022614 Interstitial nephritis acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005956-18 Sponsor Protocol Number: TIN Start Date*: 2008-01-18
    Sponsor Name:Timo Jahnukainen
    Full Title: Tubulointerstitiaalinefriitti - Riskitekijöiden kartoitus ja lääkehoidon vaikutus sairauden kulkuun.
    Medical condition: Tubulointerstitiaalinefriittiä sairastavat lapset
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048302 Tubulointerstitial nephritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020968-38 Sponsor Protocol Number: CNTO136LUN2001 Start Date*: 2011-03-17
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lup...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000243-80 Sponsor Protocol Number: MSV_LE Start Date*: 2022-05-26
    Sponsor Name:Hospital Universitario Rio Hortega
    Full Title: PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF MESENCHYMAL CELLS (MSV-allo®) IN THE TREATMENT OF LUPUS NEPHRITIS.
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005772-19 Sponsor Protocol Number: CAIN457Q12301E1 Start Date*: 2022-07-12
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) SK (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018329-20 Sponsor Protocol Number: LN-LAQ-201 Start Date*: 2010-05-07
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combinati...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025140 Lupus nephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000594-69 Sponsor Protocol Number: 211LE202 Start Date*: 2014-06-20
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002179-34 Sponsor Protocol Number: SLE01_ENK Start Date*: 2005-08-10
    Sponsor Name:Euro Nippon Kayaku GmbH
    Full Title: SAFETY AND EFFICACY STUDY ON DEOXYSPERGUALIN (NKT-01) IN PATIENTS WITH UNCONTROLLED LUPUS NEPHRITIS RECEIVING ORAL CORTICOSTEROIDS AND PRIOR TREATMENT OF STANDARD IMMUNOSUPPRESSIVE THERAPY - a pros...
    Medical condition: Systemic lupus erythrematosus (SLE) is an aggressive autoimmune disease. The chronic inflammatory processes involve many organs like the skin, lung, kidneys, central and peripheral nervous system, ...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10025140 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003201-34 Sponsor Protocol Number: U2970g Start Date*: 2016-08-07
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
    Medical condition: ISN/RPS 2003 Class III or IV Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003155-38 Sponsor Protocol Number: CNTO1959LUN2001 Start Date*: 2020-08-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005568-79 Sponsor Protocol Number: 80202135LUN2001 Start Date*: 2021-11-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Nipocalimab in Adult Participants with Active Lupus Nephritis
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001619-35 Sponsor Protocol Number: P1200_41 Start Date*: 2017-06-01
    Sponsor Name:Cliniques Universitaires Saint-lus, Université catholique de Louvain
    Full Title: Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004518-15 Sponsor Protocol Number: 28113 Start Date*: 2008-08-05
    Sponsor Name:Merck Serono International
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025140 Lupus nephritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001442-29 Sponsor Protocol Number: D3461C00007 Start Date*: 2016-01-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002159-32 Sponsor Protocol Number: 211LE201 Start Date*: 2012-03-30
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) BE (Completed) DE (Completed) ES (Prematurely Ended) HU (Completed) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005856-32 Sponsor Protocol Number: RITULUP Start Date*: 2012-05-21
    Sponsor Name:Fundación Progreso y Salud
    Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment
    Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003230-93 Sponsor Protocol Number: CCFZ533X2202 Start Date*: 2018-05-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients wi...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004917-41 Sponsor Protocol Number: WX17801 Start Date*: 2005-09-05
    Sponsor Name:Aspreva International Ltd.
    Full Title: A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in s...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    4.1 10025140 Low
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002221-36 Sponsor Protocol Number: 28779 Start Date*: 2008-10-17
    Sponsor Name:Merck Serono International, An affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: A Phase II/III, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of atacicept in combination with corticosteroids and sequential therapy with cyclophosphamide ...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025140 Lupus nephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003364-51 Sponsor Protocol Number: AUR-VCS-2012-01 Start Date*: 2014-10-24
    Sponsor Name:Aurinia Pharmaceuticals Inc.
    Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis
    Medical condition: Active lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 11:37:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA